Stan Smith bought $251K of MAIA Biotechnology (MAIA)
Executed Nov 1 2024, disclosed Nov 4 2024, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 4 2024), the stock returned -20.0% (delay-adjusted); from the execution session (Nov 1 2024), -23.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Stan Smith (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in MAIA Biotechnology, Inc. (MAIA). Across 1 priced purchase filing, the average 21-session return was +3.6% from execution and +2.1% from disclosure (delay-adjusted; derived). The largest single filing was $100K of MAIA (75,000 sh × $1.34, as filed), executed Jun 1.
Healthcare · MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targete…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→75,000 sh × $1.34
Exec Jun 1
Filed Jun 2 · 9:01 AM ET